Novo Nordisk aims to submit hemophilia drug for approval this year

Phase III results have confirmed Novo Nordisk’s faith in concizumab, which treats hemophilia A and B, and the company is now expecting to submit the drug for regulatory approval in H2 2022.

One of Novo's potential hemophilia drugs has demonstrated the desired effects in a phase III trial, dubbed Explorer 7

Before the year is over, Novo Nordisk will have submitted hemophilia drug concizumab for review by regulatory authorities, the company reports in its first quarterly report for 2022 on Friday.

The expectation is based on results from a phase III study, which has investigated the drug as a preventive treatment for people with the bleeding disorders, hemophilia A and B, with inhibitors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs